TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
10x Genomics ( (TXG) ) has provided an update.
On November 12, 2025, Eric S. Whitaker announced his retirement as Chief Legal Officer of 10x Genomics, Inc., effective January 1, 2026, after over eight years of service. He will transition to Strategic Counsel, while Dr. Randy Wu will succeed him as General Counsel and Secretary. This leadership change marks a significant transition for the company, with Whitaker continuing to offer his expertise and Dr. Wu bringing his extensive legal background to the role.
The most recent analyst rating on (TXG) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on 10x Genomics stock, see the TXG Stock Forecast page.
Spark’s Take on TXG Stock
According to Spark, TipRanks’ AI Analyst, TXG is a Neutral.
10x Genomics’ stock score is primarily influenced by its strong technical performance, with the stock trading above key moving averages. However, financial performance challenges, including negative profitability and revenue growth, weigh heavily on the score. The valuation is impacted by a negative P/E ratio, and while the earnings call highlighted some positive developments, ongoing macroeconomic challenges and funding uncertainties remain significant risks.
To see Spark’s full report on TXG stock, click here.
More about 10x Genomics
Average Trading Volume: 2,697,602
Technical Sentiment Signal: Sell
Current Market Cap: $2.11B
For a thorough assessment of TXG stock, go to TipRanks’ Stock Analysis page.